Glatiramer Acetate or Interferon-?? for Multiple Sclerosis? Academic Article uri icon

abstract

  • Abstract The 1990s, the decade of the brain, have seen major advances in the management of multiple sclerosis (MS). For the first time, effective agents are available for the treatment of relapsing-remitting MS. These include glatiramer acetate ('Copaxone') and 3 varieties of recombinant human interferon-β (IFNβ): IFNβ-1b ('Betaseron'/'Betaferon') and 2 types of IFNβ-1a ('Avonex'and 'Rebif'). The modes of action of all these agents are not fully understood; however, recent advances in our understanding of the immunopathogenesis of MS suggest that the immunomodulatory properties of these drugs are involved in their effects in the disease. Based on evidence accumulated in major clinical trials and post- marketing experience, all 4 medications reduce relapse rates by about one-third and may slow disease progression. The interferons have a beneficial effect on disease activity as …

publication date

  • January 1, 1999